Top-News
Pharmazeutika Schweden

BioInvent International News

Aktie
WKN:  A2QJRW ISIN:  SE0015244520 US-Symbol:  BOVNF
2,42 €
+0,125 €
+5,45%
14:13:42 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
58,47 Mio.
Marktkapitalisierung *
127,46 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 27.12.2021

BioInvent International News

06.09.22 - ACCESSWIRE
BioInvent Completes the Planned Dose-Escalation in Phase 1/2a trial of BI-1808 in Advanced Malignancies
LUND, SWEDEN / ACCESSWIRE / September 6, 2022 / BioInvent International (STO:BINV)
25.08.22 - ACCESSWIRE
BioInvent International AB: Interim Report January-June 2022
LUND, SWEDEN / ACCESSWIRE / August 25, 2022 / BioInvent International (STO:BINV)
01.08.22 - ACCESSWIRE
BioInvent Enrolls First Patient in Phase 1/2a Trial of BI-1607 in HER2 Positive Solid Tumors
LUND, SWEDEN / ACCESSWIRE / August 1, 2022 / BioInvent International (STO:BINV)
29.07.22 - ACCESSWIRE
Change in the Number of Shares and Votes in BioInvent International AB
LUND, SWEDEN / ACCESSWIRE / July 29, 2022 / BioInvent International (STO:BINV)
12.07.22 - ACCESSWIRE
Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022
LUND, SWEDEN / ACCESSWIRE / July 12, 2022 / BioInvent International ("BioInvent") (STO:BINV) (Nasdaq Stockholm:BINV) Extraordinary General Meeting (the "EGM") today ...
28.06.22 - ACCESSWIRE
BioInvent and Transgene Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA(R)
LUND, SWEDEN / ACCESSWIRE / June 28, 2022 / BioInvent International (STO:BINV)
27.06.22 - ACCESSWIRE
Transgene and BioInvent Announce Positive Progress for BT-001
LUND, SE / ACCESSWIRE / June 27, 2022 / BioInvent International (STO:BINV)
16.06.22 - ACCESSWIRE
Notice to Extraordinary General Meeting in BioInvent International AB
LUND, SE / ACCESSWIRE / June 16, 2022 / BioInvent International (STO:BINV)
16.06.22 - ACCESSWIRE
Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent
LUND, SWEDEN / ACCESSWIRE / June 16, 2022 / BioInvent International AB ("BioInvent") (NASDAQ Stockholm:BINV), a biotech company focused on the discovery and development ...
09.06.22 - ACCESSWIRE
BioInvent Appoints Sylvie Ryckebusch as Chief Business Officer
Over 20 years' experience as pharmaceutical business development executive Will join BioInvent's executive management team LUND, SE / ACCESSWIRE / June 09, 2022 / ...
03.05.22 - ACCESSWIRE
BioInvent's BI-1206 to Advance into Expansion Stage of Phase 1/2a Study in NHL after a Productive End-of-Phase 1 FDA Meeting
LUND, SWEDEN / ACCESSWIRE / May 3, 2022 / BioInvent International (STO:BINV)
28.04.22 - ACCESSWIRE
Resolutions at BioInvent's Annual General Meeting 2022
LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)
28.04.22 - ACCESSWIRE
BioInvent Receives Milestone Payment from Bayer/Hope Medicine Licensing Agreement
LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)
27.04.22 - ACCESSWIRE
BioInvent International AB: Interim Report January-March 2022
LUND, SE / ACCESSWIRE / April 27, 2022 / BioInvent International (STO:BINV)
07.04.22 - ACCESSWIRE
BioInvent International AB publishes Annual Report 2021
LUND, SE / ACCESSWIRE / April 7, 2022 / BioInvent International (STO:BINV)
28.03.22 - ACCESSWIRE
Notice to Annual General Meeting in BioInvent International AB
LUND, SWEDEN / ACCESSWIRE / March 28, 2022 / BioInvent International (STO:BINV)
08.03.22 - ACCESSWIRE
BioInvent and Transgene Announce Poster Presentation on BT-001, a Novel Antibody-Encoding Oncolytic Virus, at AACR 2022
Preclinical Data Shows the Robust Anti-​Tumoral Activity of BT-001, Including Its Highly Effective and Safe Therapeutic Strategy of Targeting CLTA-4
08.03.22 - ACCESSWIRE
BioInvent's BI-1607 to Extend Reach of Anti-FcyRIIB Approach to Breast Cancer
Preclinical Proof of Concept for Second Anti-​FcyRIIB Antibody BI-1607 to be Presented at AACR
08.03.22 - ACCESSWIRE
BioInvent AACR Data Boost Prospects for BI-1808
LUND, SE / ACCESSWIRE / March 8, 2022 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the ...
23.02.22 - ACCESSWIRE
BioInvent International AB (publ) Year-End Report January 1 - December 31, 2021
LUND, SWEDEN / ACCESSWIRE / February 23, 2022 / BioInvent International (STO:BINV)

Newssuche

Videos

08:55 Uhr -6,48%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »